Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Benzoyl peroxide warning delay urged by NDMA until photocarcinogenicity studies done.

This article was originally published in The Tan Sheet

Executive Summary

NDMA QUESTIONS SCIENTIFIC BASIS FOR BENZOYL PEROXIDE SUN EXPOSURE WARNING in July 17 comments to FDA. Responding to FDA's proposal to require a warning to avoid "unnecessary sun exposure" on products containing benzoyl peroxide ("The Tan Sheet" Feb. 20, p. 6), the Nonprescription Drug Manufacturers Association asserted that the warning is "not supported by scientific evidence" and should be considered "only after the NDMA-sponsored photocarcinogenicity studies that FDA requested have been completed."
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel